Tauriga Sciences Inc. to Further Expand & Diversify its Product Offerings with the Launch of CBD Infused Honey

This Product is Comprised of Raw Linden Honey Infused with 500mg CBD / Each Jar Contains 20 Servings (25mg CBD per Serving)

 NEW YORK, NY, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced a new product offering to help ensure the expansion and diversification of the Company’s proprietary product offerings.  This is in response to the Company’s fast growing E-Commerce business segment as well as the continually increasing customer base.

After evaluating numerous potential new product offerings, the Company has decided to launch this CBD Infused Linden Honey (“CBD Honey”) product.  This new product will be infused with 500mg of CBD per Jar (“Unit”) and each jar contains 20 servings (25mg CBD per serving).  This product will also be Kosher Certified and of the highest quality.  The Manufacturer’s Suggested Retail Price (“MSRP”) is expected to be set at $49.99 USD per Jar.  This CBD Honey (16 oz. Jars) will be available exclusively on the Company’s E-Commerce Website (www.taurigum.com).

Raw Linden Honey is a tough honey to produce as the Linden trees are only in bloom 7-10 days annually. The honey has been described as having a very fresh aroma, described as: minty, menthol, camphor, balsamic, etc. Excellent honey for tea, desserts, muffins, hot cereal - you name it!  The blooming season for Linden trees is generally the first week in July in the Northern Hemisphere. 

Tauriga’s CEO Seth M. Shaw: “The Company has been both pleased and excited by the sharp increase in its online E-Commerce business.  However, even more exciting, is the continual growth of the Company’s prospective customer base.  As the customer base increases, so does the Company’s desire to expand and diversify product offerings to support this enhanced audience.  It is our policy to carefully listen to the advice and recommendations of our customers.  In this spirit, the Company has decided to launch this innovative CBD Honey product. Additionally, more products are on the way!” 

In other news, the Company is close to achieving an important corporate milestone.  The Company’s Instagram Page, @taurigum, has secured more than 9,700 Followers.  Once the 10,000 Followers threshold is reached, the Company believes that there will be a positive effect on its E-Commerce Business.  

Link to @taurigum Instagram Page:

Link: https://www.instagram.com/taurigum/

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website:  www.tauriga.com

E-Commerce Website:  www.taurigum.com

Attachment

• Dec 8 PR Image